In 401 Japanese adults with type 2 diabetes, 52 weeks of once-daily oral orforglipron (3, 12 or 36 mg) caused adverse events in 85%, mostly mild; discontinuation for adverse events was 5%, 8% and 14% by dose. No severe hypoglycaemia occurred.
RCTn = 401
Yabe et al. Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial